Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug;18(8):E299-304.
doi: 10.1111/j.1469-0691.2012.03847.x. Epub 2012 Apr 27.

Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010

M Colafigli  1 , C Torti, E M Trecarichi, L Albini, A Rosi, V Micheli, N Manca, G Penco, B Bruzzone, G Punzi, P Corsi, G Parruti, P Bagnarelli, L Monno, A Gonnelli, R Cauda, S Di Giambenedetto; ARCA, UCSC and Brescia HIV resistance study groups
Collaborators, Affiliations

Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010

M Colafigli et al. Clin Microbiol Infect. 2012 Aug.

Abstract

Prevalence and predictors of transmitted drug resistance (TDR), defined as the presence of at least one WHO surveillance drug resistance mutation (SDRM), were investigated in antiretroviral-naïve HIV-1-infected patients, with a genotypic resistance test (GRT) performed ≤6 months before starting cART between 2000 and 2010. 3163 HIV-1 sequences were selected (69% subtype B). Overall, the prevalence of TDR was 12% (13.2% subtype B, 9% non-B). TDR significantly declined overall and for the single drug classes. Older age independently predicted increased odds of TDR, whereas a more recent GRT, a higher HIV-RNA and C vs. B subtype predicted lower odds of TDR.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Evolution of resistance (at least one major IAS mutation) by calendar year from 2000 to 2010 in naive patients with non acute/non recent infection (A, n=2,937), evolution of the prevalence of B, non-B and unknown subtypes (B) and evolution of the prevalence of drug resistance in B subtype (C) and in non-B subtypes (D). NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
Figure 1
Figure 1
Evolution of resistance (at least one major IAS mutation) by calendar year from 2000 to 2010 in naive patients with non acute/non recent infection (A, n=2,937), evolution of the prevalence of B, non-B and unknown subtypes (B) and evolution of the prevalence of drug resistance in B subtype (C) and in non-B subtypes (D). NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
Figure 1
Figure 1
Evolution of resistance (at least one major IAS mutation) by calendar year from 2000 to 2010 in naive patients with non acute/non recent infection (A, n=2,937), evolution of the prevalence of B, non-B and unknown subtypes (B) and evolution of the prevalence of drug resistance in B subtype (C) and in non-B subtypes (D). NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
Figure 1
Figure 1
Evolution of resistance (at least one major IAS mutation) by calendar year from 2000 to 2010 in naive patients with non acute/non recent infection (A, n=2,937), evolution of the prevalence of B, non-B and unknown subtypes (B) and evolution of the prevalence of drug resistance in B subtype (C) and in non-B subtypes (D). NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
See this image and copyright information in PMC

References

    1. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008 May 15;358(20):2095–106. - PMC - PubMed
    1. Daar ES, Tierney C, Fischl MA, et al. Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1: A Randomized Trial. Ann Intern Med. 2011 Apr 5;154(7):445–456. Epub 2011 Feb 14. - PMC - PubMed
    1. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008 Aug 23;372(9639):646–55. - PubMed
    1. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008 Jul 31;22(12):1389–97. - PubMed
    1. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009 Sep 5;374(9692):796–806. Epub 2009 Aug 3. Erratum in: Lancet. 2009 Dec 19-2010 Jan 1; 374(9707):2054. Lancet. 2009 Sep 5;374(9692):786. - PubMed

Publication types

Substances